| Autor: |
Debrabander M; JANSSEN RES FDN,B-2340 BEERSE,BELGIUM. VRIE UNIV BRUSSELS,UNIV ZIEKENHUIS BRUSSELS,B-1090 JETTE,BELGIUM., Roels V, Vogels O, Demoen B, Deridder R, Jagers E, Baisier A, Doolaege R, Decoster R, Aerts F, Vandebroek J, Decree J, Verhaegen H, Dewaele M, Distelmans W, Vanbelle S, Storme G |
| Jazyk: |
angličtina |
| Zdroj: |
International journal of oncology [Int J Oncol] 1992 Aug; Vol. 1 (3), pp. 337-40. |
| DOI: |
10.3892/ijo.1.3.337 |
| Abstrakt: |
In search for clues to the potential immunomodulating mechanism of action of levamisole which might be used as monitoring parameters, we have determined a variety of cytokines in the peripheral blood of volunteers and carcinoma patients before and after a single or a 3-day-treatment with 150 mg/day. In cancer patients no changes could be detected 4 days after a 3-day-treatment course in the levels of TNF-alpha, IL-1beta, IL-2 or IL-6. In a placebo-controlled volunteer study the same treatment did not affect the levels of beta2-microglobulin, IL-1beta, IL-1alpha, IL-2 or IL-6. However, 24hr after the last treatment the concentration of neopterin was slightly but significantly increased and the concentration of soluble IL-2 receptors decreased. A single treatment failed to produce such an effect. It is suggested that the measurement of neopterin and soluble IL-2 receptors may provide useful information in future trials. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
